Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $6.12

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, three have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.1167.

A number of research analysts have recently commented on the stock. Craig Hallum upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Citigroup raised shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Citizens Jmp raised shares of Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 price target for the company in a research note on Monday, January 5th. Finally, Wells Fargo & Company increased their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th.

Ironwood Pharmaceuticals Stock Performance

IRWD opened at $4.64 on Friday. The stock’s 50 day moving average price is $3.42 and its 200-day moving average price is $1.97. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.78. The stock has a market cap of $754.84 million, a price-to-earnings ratio of 29.00 and a beta of 0.18.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $122.06 million during the quarter, compared to analysts’ expectations of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%. As a group, analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Inspire Investing LLC lifted its stake in Ironwood Pharmaceuticals by 138.3% in the second quarter. Inspire Investing LLC now owns 552,420 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 320,595 shares during the period. Acadian Asset Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 160.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock worth $3,878,000 after purchasing an additional 1,630,726 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 76.1% during the second quarter. Los Angeles Capital Management LLC now owns 1,211,155 shares of the biotechnology company’s stock valued at $869,000 after purchasing an additional 523,368 shares in the last quarter. Focus Partners Advisor Solutions LLC boosted its stake in shares of Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 29,409 shares in the last quarter. Finally, Armistice Capital LLC increased its holdings in Ironwood Pharmaceuticals by 17.9% during the second quarter. Armistice Capital LLC now owns 16,150,000 shares of the biotechnology company’s stock valued at $11,583,000 after buying an additional 2,450,000 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.